Publications by authors named "F Baert"

Claim this Profile
V
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.
Geert R D'Haens, Mark Löwenberg, Filip Baert, Peter Bossuyt, Tamás Molnár

Lancet Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-stakeholder validation of an evidence-based core set of quality indicators for IBD in Belgium.
Liselotte Fierens, Frank E Rademakers, Peter Bossuyt, Filip Baert, Didier Baert

BMC Health Serv Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's Disease.
Suzanne I Anjie, Geert R D'Haens, Filip Baert, Peter Bossuyt, Frank Hoentjen

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure.
A Cremer, A Mansour, T Lobaton, P Bossuyt, J Rahier, F Baert

Acta Gastroenterol Belg· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of ustekinumab in Crohn's disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data.
Laurent Peyrin-Biroulet, Maciej Nazar, Anna Sheahan, Anja Geldhof, Ahlem Azzabi, Filip Baert

Dig Liver Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis